421 related articles for article (PubMed ID: 38550587)
1. Targeting YAP1 to improve the efficacy of immune checkpoint inhibitors in liver cancer: mechanism and strategy.
Gao Y; Gong Y; Lu J; Hao H; Shi X
Front Immunol; 2024; 15():1377722. PubMed ID: 38550587
[TBL] [Abstract][Full Text] [Related]
2. Immune checkpoint inhibitor resistance in hepatocellular carcinoma.
Wang Z; Wang Y; Gao P; Ding J
Cancer Lett; 2023 Feb; 555():216038. PubMed ID: 36529238
[TBL] [Abstract][Full Text] [Related]
3. Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma.
Xing R; Gao J; Cui Q; Wang Q
Front Immunol; 2021; 12():783236. PubMed ID: 34899747
[TBL] [Abstract][Full Text] [Related]
4. Potential experimental immune checkpoint inhibitors for the treatment of cancer of the liver.
Hewitt DB; Rahnemai-Azar AA; Pawlik TM
Expert Opin Investig Drugs; 2021 Aug; 30(8):827-835. PubMed ID: 34102935
[No Abstract] [Full Text] [Related]
5. Viral status, immune microenvironment and immunological response to checkpoint inhibitors in hepatocellular carcinoma.
Ho WJ; Danilova L; Lim SJ; Verma R; Xavier S; Leatherman JM; Sztein MB; Fertig EJ; Wang H; Jaffee E; Yarchoan M
J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32303615
[TBL] [Abstract][Full Text] [Related]
6. Radiation and Immune Checkpoint Inhibitors: Combination Therapy for Treatment of Hepatocellular Carcinoma.
Chami P; Diab Y; Khalil DN; Azhari H; Jarnagin WR; Abou-Alfa GK; Harding JJ; Hajj J; Ma J; El Homsi M; Reyngold M; Crane C; Hajj C
Int J Mol Sci; 2023 Nov; 24(23):. PubMed ID: 38069095
[TBL] [Abstract][Full Text] [Related]
7. Using mouse liver cancer models based on somatic genome editing to predict immune checkpoint inhibitor responses.
Yuen VW; Chiu DK; Law CT; Cheu JW; Chan CY; Wong BP; Goh CC; Zhang MS; Xue HD; Tse AP; Zhang Y; Lau HY; Lee D; Au-Yeung RKH; Wong CM; Wong CC
J Hepatol; 2023 Feb; 78(2):376-389. PubMed ID: 36455783
[TBL] [Abstract][Full Text] [Related]
8. Immune checkpoint inhibitors in the treatment of hepatocellular carcinoma.
Akbulut Z; Aru B; Aydın F; Yanıkkaya Demirel G
Front Immunol; 2024; 15():1379622. PubMed ID: 38638433
[TBL] [Abstract][Full Text] [Related]
9. The progress of research on immune checkpoint inhibitor resistance and reversal strategies for hepatocellular carcinoma.
Kou L; Xie X; Chen X; Li B; Li J; Li Y
Cancer Immunol Immunother; 2023 Dec; 72(12):3953-3969. PubMed ID: 37917364
[TBL] [Abstract][Full Text] [Related]
10. Immune checkpoint inhibitors in HCC: Cellular, molecular and systemic data.
Harkus U; Wankell M; Palamuthusingam P; McFarlane C; Hebbard L
Semin Cancer Biol; 2022 Nov; 86(Pt 3):799-815. PubMed ID: 35065242
[TBL] [Abstract][Full Text] [Related]
11. Combinatorial targeting of immune checkpoints and epigenetic regulators for hepatocellular carcinoma therapy.
Akce M; El-Rayes BF; Wajapeyee N
Oncogene; 2023 Mar; 42(14):1051-1057. PubMed ID: 36854723
[TBL] [Abstract][Full Text] [Related]
12. T cell-mediated targeted delivery of tadalafil regulates immunosuppression and polyamine metabolism to overcome immune checkpoint blockade resistance in hepatocellular carcinoma.
Wang X; Zhang Q; Zhou J; Xiao Z; Liu J; Deng S; Hong X; Huang W; Cai M; Guo Y; Huang J; Wang Y; Lin L; Zhu K
J Immunother Cancer; 2023 Feb; 11(2):. PubMed ID: 36813307
[TBL] [Abstract][Full Text] [Related]
13. Immune checkpoint inhibitors in hepatocellular carcinoma: emerging challenges in clinical practice.
Pinter M; Scheiner B; Pinato DJ
Lancet Gastroenterol Hepatol; 2023 Aug; 8(8):760-770. PubMed ID: 37327807
[TBL] [Abstract][Full Text] [Related]
14. Cancer Immunotherapy - Immune Checkpoint Inhibitors in Hepatocellular Carcinoma.
Bai J; Liang P; Li Q; Feng R; Liu J
Recent Pat Anticancer Drug Discov; 2021; 16(2):239-248. PubMed ID: 33583384
[TBL] [Abstract][Full Text] [Related]
15. Clinical outcomes of immune checkpoint inhibitors in unresectable or metastatic combined hepatocellular-cholangiocarcinoma.
Jang YJ; Kim EJ; Kim HD; Kim KP; Ryu MH; Park SR; Choi WM; Lee D; Choi J; Shim JH; Kim KM; Lim YS; Lee HC; Ryoo BY; Yoo C
J Cancer Res Clin Oncol; 2023 Aug; 149(10):7547-7555. PubMed ID: 36971796
[TBL] [Abstract][Full Text] [Related]
16. Dihydroartemisinin broke the tumor immunosuppressive microenvironment by inhibiting YAP1 expression to enhance anti-PD-1 efficacy.
Peng Q; Li S; Shi X; Guo Y; Hao L; Zhang Z; Ji J; Zhao Y; Li C; Xue Y; Liu Y
Phytother Res; 2023 May; 37(5):1740-1753. PubMed ID: 36576358
[TBL] [Abstract][Full Text] [Related]
17. Advances in Immune Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma.
Chen Y; Hu H; Yuan X; Fan X; Zhang C
Front Immunol; 2022; 13():896752. PubMed ID: 35757756
[TBL] [Abstract][Full Text] [Related]
18. YAP1 activation and Hippo pathway signaling in the pathogenesis and treatment of intrahepatic cholangiocarcinoma.
Ko S; Kim M; Molina L; Sirica AE; Monga SP
Adv Cancer Res; 2022; 156():283-317. PubMed ID: 35961703
[TBL] [Abstract][Full Text] [Related]
19. The application basis of immuno-checkpoint inhibitors combined with chemotherapy in cancer treatment.
Shi MY; Liu HG; Chen XH; Tian Y; Chen ZN; Wang K
Front Immunol; 2022; 13():1088886. PubMed ID: 36703971
[TBL] [Abstract][Full Text] [Related]
20. PD-1/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy.
Li Q; Han J; Yang Y; Chen Y
Front Immunol; 2022; 13():1070961. PubMed ID: 36601120
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
